Photodynamic Diagnosis of Bladder Cancer

Evidence Base

This section has been designed to provide Trusts wishing to progress with implementation of the technology with the evidence base required to agree a Business Case and to ensure that the technology being adopted is safe and complies with relevant clinical governance frameworks locally and nationally.

In this section you will find a short background to national standards, relevant trial reports, and supporting evidence, other useful reference papers and useful websites.


NTAC Project Data

Methods of quantitative and qualitative measurement and evaluation of the clinical utility of implementing the diagnostic technique were developed by project teams from the NTAC project sites (see Contacts and Links). These were used in the determination of the impact of the technology on patient outcomes and support requirements, hospital resource requirements and the clinical utility of adoption the technology.

The evaluation measures and values were subjected to independent analysis undertaken by the NHS Technology Adoption Centre and York Health Economics Consortium. The data was further reviewed by the NHS Information Centre for Health and Social Care.

The following reports were created as part of this project: 

PDD slides shows a summary presentation of the data collected during this project.

PDD Headline Report shows a headline of project data.

PDD Data Analysis Report shows a full breakdown of the data collected.

PDD Economic Report shows a full health economic analysis on this technology.

PDD Costing Model demonstrates a full costing model for this technology.

 


Background to National Standards

Bladder cancer is caused by the uncontrolled growth of the cells lining the bladder wall. If the cancer hasn't grown from the bladder lining into the muscle of the bladder it is called non-muscle invasive bladder cancer - this is the most common type of bladder cancer and can be treated by removing it from the bladder wall. The procedure is called transurethral resection of bladder tumour (TURBT).

The use of photodynamic diagnosis of bladder cancer (PDD) is sign posted by the Map of Medicine, the European Association of Urology, the Scottish Intercollegiate Guidelines Network and the British Association of Urological Surgeons. The availability of PDD which is concurrent with transurethral resection of bladder tumour (TURBT) offers the potential to streamline the number of subsequent surgeries undertaken for primary bladder cancer each year, with length of stay savings of up to 0.24 days per patient (this will vary depending on local protocols). This would equate to a saving of approximately 2,116 bed days in the UK over a five year period and would remove the inefficiencies associated with unnecessary follow-up protocol post-operatively.

The National Institute for Health and Clinical Excellence (NICE) completed a Health Technology Assessment on the PDD technology in January 2010 which found that photodynamic diagnosis has higher sensitivity but lower specificity than white light cystoscopy and cytology, respectively in detecting bladder cancer. Diagnostic strategies involving photodynamic diagnosis provide additional benefits in terms of more complete tumour removal at initial surgery (TURBT) with a subsequent reduction in later cancer recurrence at a cost that society might be willing to pay.


Health Technology Assessment, other Systematic Reviews, and Key Studies

Health Technology Assessment, other Systematic Reviews, and Key Studies

1.

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010 Jan; 14(4):1-356.

http://www.urotoday.com/bladder-cancer-1038/137-bladder-cancer-1038/34111-systematic-review-of-the-clinical-effectiveness-and-costeffectiveness-of-photodynamic-diagnosis-and-urine-biomarkers-fish-immunocyt-nmp22-and-cytology-for-the-detection-and-followup-of-bladder-cancer-abstract-2227027.html

2.

HTA Technology Assessment Report. National Institute for Health Research Health Technology Assessment programme. Volume 14, number 4. January 2010.

http://www.hta.ac.uk/project/1713.asp

3.

Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations.
European Urology. April 2010. Volume 57, Issue 4, pages 607-614.

http://www.ncbi.nlm.nih.gov/pubmed/20116164

4.

Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies.
European Urology. April 2010. Volume 57, Issue 4, pages 595-606. 

http://www.ncbi.nlm.nih.gov/pubmed/20004052

5.

The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.

http://www.ncbi.nlm.nih.gov/pubmed/20089091

6.

Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.

http://www.ncbi.nlm.nih.gov/pubmed/19473068

7.

Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.

http://www.ncbi.nlm.nih.gov/pubmed/19441882

8.

The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer.

http://www.ncbi.nlm.nih.gov/pubmed/19356647

9.

Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.

http://www.ncbi.nlm.nih.gov/pubmed/19330681

10.

Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.

http://www.ncbi.nlm.nih.gov/pubmed/19076151

11.

Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?

http://www.ncbi.nlm.nih.gov/pubmed/18793301

12.

Incorporating fluorescence cystoscopy for the diagnosis of bladder cancer into clinical practice.

http://www.ncbi.nlm.nih.gov/pubmed/18577979

13.

Photodynamic diagnosis in urology: state-of-the-art.

http://www.ncbi.nlm.nih.gov/pubmed/18096307

14.

The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. 

http://www.ncbi.nlm.nih.gov/pubmed/17921969

15.

A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

http://www.ncbi.nlm.nih.gov/pubmed/17499291

16.

Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.

http://www.ncbi.nlm.nih.gov/pubmed/14665861


Other useful reference papers

Department of Health

Cancer Commissioning Guidance, January 2009

Click here to view this guidance

Guide to practice-based commissioners in developing good cancer care services, June 2009.

Click hereto view this guide

Cancer Reform Strategy - 2010

Click hereto view this strategy


Other useful web links

National Cancer Intelligence Network

November 2009: Report and Presentations from the NCIN Co-morbidity Data Collection Workshop.

http://www.ncin.org.uk/data/comorbidity.shtml

Transforming Care for Cancer Inpatients - Spreading the Winning Principles and Good Practice, July 2009

Click here to view this publication


Ensuring Better Treatment: Going Further on Cancer Waits - An Improvement guide for supporting sustainable delivery, February 2009.

Click here to view this guide


Locally Developed CQUIN Schemes 2009/10
http://www.institute.nhs.uk/world_class_commissioning/pct_portal/cquin_schemes.html


Measuring Surgical Outcomes

http://www.rcseng.ac.uk/media/media-background-briefings-and-statistics/measuring-surgical-outcomes


Disclaimer

Neither the NHS Technology Adoption Centre (NTAC) nor its contributors are responsible for the contents of any off-site pages referenced. The user specifically acknowledges that neither NTAC nor its contributors is liable for the defamatory, offensive, or illegal conduct of other users, links, or third parties and that the risk of injury from the foregoing rests entirely with the user.


Links from the NTAC How to Why to Guides site on the World Wide Web to other sites do not constitute any endorsement. These links are provided as an information service only. It is the responsibility to the web surfer to evaluate the content and usefulness of information obtained from other sites.

Downloadable Resources

Follow Us

For the latest news on our activities follow us on Twitter and Linked-In

twitter
linkedin
rss

Join The Discussion

Welcome to the How To Why To Guide

The NHS Technology Adoption Centre How To Why To Guides. They are designed to provide you with information about innovative medical technologies, the benefits and barriers to adoption along with practical implementation tools for your organisation.

Please agree to the terms and conditions below before entering the site.

1. Agreement

1.1 This freely accessible version of the How To Why To Guide is a generalised assessment version of a select number of Technology Implementation Projects undertaken by the NHS Technology Adoption Centre ("NTAC) that has been provided to allow you to see how adoption processes operates (the ´Guides´). The Guides are produced and made available by The NHS Technology Adoption Centre. By accessing the Guides you ("you") agree to these Terms.

1.2 These Terms form the agreement between you and us. If you do not agree to be legally bound by these Terms please leave this section of the website immediately. Your continued access and use of the website and/or the How To Why To Guide will amount to acceptance.

1.3 You are hereby granted a non-transferable, non-exclusive licence to view the Guides for your personal assessment and non-commercial purposes until your access is terminated by us.

2. Disclaimer

2.1 Liability

2.1.1 Neither NTAC, nor its contributors shall be held liable for any improper or incorrect use of the information described and/or contained on this site and NTAC assumes no responsibility for anyone´s use of the information.

2.1.2 In no event shall NTAC, or contributors be liable for any direct, indirect, incidental, special, exemplary, or consequential damages (including, but not limited to, procurement or substitute goods or services; loss of use, data, or profits; or business interruption) however caused and on any theory of liability, whether in contract, strict liability, or tort (including negligence or otherwise) arising in any way out of the use of this site or system.

2.1.3 This disclaimer of liability applies to any damages or injury, including but not limited to those caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortuous behaviour, negligence or under any other cause of action.

2.2 Warranties/Accuracy of Information

2.2.1 Although the data found using the NTAC site has been produced and processed from sources believed to be reliable, no warranty expressed or implied is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information.

2.2.2 This disclaimer applies to both isolated and aggregate uses of the information. NTAC provides this information on an "as is" basis. All warranties of any kind express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses and non-infringement of proprietary rights ARE DISCLAIMED.

2.2.3 Changes may be periodically added to the information contained in our "How to why to guides "; these changes may or may not be incorporated in any new version of the guide. If you have obtained information on the NTAC site from a source other than NTAC, please be aware that electronic data can be altered subsequent to original distribution. Data can also quickly become out-of-date.

2.3 Endorsement

2.3.1 NTAC is a distributor of content sometimes supplied by third parties and users. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by third parties, including information providers, users, or others, are those of the respective author(s) or distributor(s) and do not necessarily state or reflect those of NTAC and shall not be used for advertising or product endorsement purposes.

2.3.2 Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favouring by NTAC.

2.4 Duty to Continue Provision of "How to why to Guides"

2.4.1 Due to the dynamic nature of the Internet, resources that are publicly available one day may require restriction of access the next, and the location of items may change as menus, homepages, and files are reorganised.

2.4.2 User expressly agrees that use of NTAC site is at the user's sole risk. Neither NTAC, any entity jointly created by them, each of their affiliates nor any of their respective employees, agency, third party content providers or licenser warrant that the service will be uninterrupted or error free.

2.5 Conflicts of Interest

2.5.1 Neither NTAC, nor its contributors, have received any corporate sponsorship nor hold any financial interest in the companies manufacturing technologies described in our How to why to Guides.

3. Restrictions and intellectual property rights

3.1 The How To Why To Guide contains copyright material, trade names and marks and other proprietary information, including, but not limited to, text, software, photos and graphics ("Content"). The Content is protected by copyright law, database rights and other intellectual property rights.

3.2 The information contained here may not be converted into any other format, or transmitted in any other way, without the consent of the authors. While we encourage hyper-links to be made to this site from other parts of the Web, the pages cannot be copied and saved onto other Web servers in order to be transmitted from those servers, without permission from NTAC. This prohibition applies to those who intend to make copies of this information to retransmit as part of other Web sites; it does not apply to other Web servers which store pages for routine caching purposes.

3.3 In the event of any authorised copying, redistribution or publication of copyright material, no changes in or deletion of author attribution, trademark legend or copyright notice shall be made. You acknowledge that you do not acquire any ownership rights by downloading copyright material.

4. Limitation of liability / indemnity

You agree to defend, indemnify, and hold harmless, NTAC, its contributors, any entity jointly created by them, their respective affiliates and their respective directors, officers, employees, and agents from and against all claims and expenses, including legal fees, arising out of the use of this site or service by user or user's account.

5. External links

5.1 Every effort is made to ensure that access to the How To Why To Guide is uninterrupted and that transmissions will be error-free. However, we cannot, due to the nature of the internet, guarantee that your access will not be suspended from time to time including to allow for repairs, maintenance or the introduction of new content or facilities.

5.2 NTAC, nor its contributors are responsible for the contents of any off-site pages referenced. The user specifically acknowledges that neither NTAC or its contributors is liable for the defamatory, offensive, or illegal conduct of other users, links, or third parties and that the risk of injury from the foregoing rests entirely with the user.

5.3 The How To Why To Guide contains links including hyperlinks which may take you outside of http://www.technologyadoptioncentre.nhs.uk/how-to-why-to-guides.html. Links are provided for your convenience, and an inclusion of any link does not imply endorsement or approval by us of the linked website, its operator or content. These links are provided as an information service only. It is the responsibility to the web surfer to evaluate the content and usefulness of information obtained from other sites.

6. Governing law

6.1 These Terms are governed by English law notwithstanding the jurisdiction where you are based. You irrevocably agree that the courts of England shall have exclusive jurisdiction to settle any dispute which may arise out of, under, or in connection with these Terms and for those purposes irrevocably submit all disputes to the jurisdiction of the English courts. The place of performance shall be England.

6.2 We provide no warranty or guarantee that the Website or information available on it complies with laws other than those of England.

6.3 If any provision (or part) of this agreement is found by any court of competent jurisdiction or administrative body to be invalid, unenforceable or illegal, the other provisions shall remain in force.

7. Further information

7.1 Further information or any queries on them can be obtained from NHS Technology Adoption Centre


I agree to the terms & conditions